



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-FAP alpha [BIBH1 (Sibrotuzumab, huF19)] Bulk Size Ab04184-3.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted mouse IgG2b Fc Silent™ antibody, based on the original mouse IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Mouse IgG2b, [Fc Silent™](#), Kappa

**Clone Number:** BIBH1 (Sibrotuzumab, huF19)

**Alternative Name(s) of Target:** Seprase; Fibroblast activation protein; Prolyl endopeptidase FAP; 170 kDa melanoma membrane-bound gelatinase; Dipeptidyl peptidase FAP; FAPalpha; Fibroblast activation protein alpha; Gelatin degradation protease FAP; Integral membrane serine protease; Post-proline cleaving enzyme; Serine integral membrane protease; SIMP; Surface-expressed protease

**UniProt Accession Number of Target Protein:** Q12884

**Published Application(s):** ELISA, FC, IHC

**Published Species Reactivity:** Human

**Immunogen:** The parental mouse antibody F19 was generated by immunizing mice with lung fibroblasts. The original humanized version of the antibody was generated by grafting of CDRs from the parental mouse antibody onto human framework regions.

**Specificity:** This antibody binds specifically to human fibroblast activation protein (FAP). This protein is a cell surface glycoprotein serine protease that participates in extracellular matrix degradation and is involved in many cellular processes including tissue remodeling, fibrosis, wound healing, inflammation and tumor growth. This antibody does not cross react with rat, mouse, rabbit or cynomolgus monkey FAP.

**Application Notes:** The binding characterization of this antibody towards surface expressed FAP was done using flow cytometry. An in vitro assay with either human complement or with human MNC as effector mechanisms revealed no detectable cytotoxic effects on FAP-expressing tumor cell line HT-1080FAP clone33. This antibody was also used in the immunohistochemical analysis of normal and neoplastic human tissues. This antibody was also capable of binding recombinant human FAP in an ELISA (WO1999057151). A phase I biodistribution study with 131I-labelled mAb F19 was carried out in 17 presurgical patients with hepatic metastases from colorectal cancer (PMID: 8201382). Another study investigated the anti-tumor activity, safety and pharmacokinetics of this antibody in patients with metastatic colorectal cancer. It

concluded that this antibody was well tolerated and safe (PMID: 12624517). In another dose escalation study of sibrotuzumab, in patients with advanced FAP-positive cancer, it was concluded that this antibody can be safely administered to patients (PMID: 12738716). Phase 1 and 2 clinical trials of sibrotuzumab did not accomplish a good outcome. The block of the enzymatic activity of FAP with small molecule inhibitors also resulted in lower survival rates for the patients (PMID: 30781344).

**Antibody First Published in:** Hofheinz et al. Stromal antigen targeting by a humanized monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. *Onkologie*. 2003 Feb;26(1):44-8. [PMID:12624517](#)

**Note on publication:** This paper investigates the safety, anti-tumor activity and pharmacokinetics of sibrotuzumab (BIBH 1), a humanized version of murine anti-FAP mAb F19.

## Product Form

**Size:** 1 mg Purified antibody in bulk size.

**Purification:** Protein A affinity purified

**Supplied In:** PBS only.

**Storage Recommendation:** Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.